Inventaire - your friends and communities are your best library

CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses

author

Hideki Hasegawa

Takato Odagiri

published in: Vaccine

date of publication: 2019-07-22

Cites articles 39

Date

Title

Authors

2020-10-16

SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans

Chad M Swanson, Daniel Sauter, Frank Kirchhoff
2018-02-06

Modeling for influenza vaccines and adjuvants profile for safety prediction system using gene expression profiling and statistical tools.

Takuo Mizukami
2017-01-23

Selectivity of Human TLR9 for Double CpG Motifs and Implications for the Recognition of Genomic DNA.

Mojca Benčina
2015-06-16

Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan

Hideki Hasegawa, Takato Odagiri
2015-06-08

Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus

Hideki Hasegawa, Takato Odagiri
2015-09-28

Species-Specific Minimal Sequence Motif for Oligodeoxyribonucleotides Activating Mouse TLR9.

Mojca Benčina
2015

CpG oligodeoxynucleotides as mucosal adjuvants
2015-08-28

Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes

Dennis Christensen, Donata Medaglini, Peter Andersen, Gianni Pozzi, Annalisa Ciabattini
2014-06-24

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
2012-06-01

The mechanism of action of MF59 - an innately attractive adjuvant formulation
2011-11-17

A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging

Tetsutaro Sata
2009-10-27

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

Amagana Dolo, Michael P. Fay, Ogobara K. Doumbo, Kazutoyo Miura, Carole A Long, Alassane Dicko, Issaka Sagara, Ousmane Guindo, Mahamadou S Sissoko, Dapa A Diallo, Ruth D Ellis, Louis H. Miller, Mohamed B Niambele, Beh Kamate, Gregory E.D. Mullen, Merepen A Guindo, Renion Saye, Mark C Pierce, Kelly M. Rausch
2008-04-21

Safety of MF59 adjuvant

Andreas Wack
2007-10-18

Recognition of microorganisms and activation of the immune response
2007-12-05

Influenza PR8 HA-specific Fab fragments produced by phage display methods

Tetsutaro Sata
2006-02-24

Pathogen recognition and innate immunity

Satoshi Uematsu
2005-03-01

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

Tetsutaro Sata, Hideki Hasegawa, Takeshi Kurata
2004-02-01

Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy
2004-02-01

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

Margot Mütsch, Matthias Bopp, Robert T. Chen
2004-08-01

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

Bill Cameron
2003-05-01

Estimating deaths due to influenza and respiratory syncytial virus.
2003-09-01

Subcellular localization of Toll-like receptor 3 in human dendritic cells
2001-10-04

CpG motifs in bacterial DNA and their immune effects

Arthur Krieg
2000-01-01

Impact of respiratory virus infections on persons with chronic underlying conditions
2000-01-01

Mechanisms of immune stimulation by bacterial DNA.
1999-01-01

Bacterial CpG DNA activates immune cells to signal infectious danger
1999-01-01

Update on influenza and rhinovirus infections
1998-12-01

Type I interferon-mediated stimulation of T cells by CpG DNA
1998-02-01

Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection
1997-09-01

CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants
1996-02-01

Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990.
1994-04-01

Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.

Article - wd:Q92182895

Welcome to Inventaire

the library of your friends and communities

learn more